About virax biolabs group ltd - VRAX
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.
VRAX At a Glance
Virax Biolabs Group Ltd.
Bo'Ness Road Newhouse
Lanarkshire, Scotland ML1 5UH
| Phone | 44-20-7788-7414 | Revenue | 12.42K | |
| Industry | Financial Conglomerates | Net Income | -5,023,750.00 | |
| Sector | Finance | 2026 Sales Growth | 96.225% | |
| Fiscal Year-end | 03 / 2027 | Employees | 26 | |
| View SEC Filings |
VRAX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 175.944 |
| Price to Book Ratio | 0.42 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.685 |
| Enterprise Value to Sales | -328.518 |
| Total Debt to Enterprise Value | -0.102 |
VRAX Efficiency
| Revenue/Employee | 477.808 |
| Income Per Employee | -193,221.154 |
| Receivables Turnover | 0.458 |
| Total Asset Turnover | 0.002 |
VRAX Liquidity
| Current Ratio | 9.968 |
| Quick Ratio | 9.968 |
| Cash Ratio | 9.40 |
VRAX Profitability
| Gross Margin | -3,472.012 |
| Operating Margin | -51,515.173 |
| Pretax Margin | -47,753.554 |
| Net Margin | -40,439.105 |
| Return on Assets | -68.111 |
| Return on Equity | -75.696 |
| Return on Total Capital | -62.862 |
| Return on Invested Capital | -72.442 |
VRAX Capital Structure
| Total Debt to Total Equity | 5.469 |
| Total Debt to Total Capital | 5.185 |
| Total Debt to Total Assets | 4.978 |
| Long-Term Debt to Equity | 4.023 |
| Long-Term Debt to Total Capital | 3.814 |